Selected Grants
MK-0616
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2030A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) OCEAN(a)-Outcomes- Olpasiran trials
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2023 - 2028V-INCLUSION
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2024 - 2027Test to Treat: A Randomized Implementation Trial to Improve LDL-C Management after Hospitalization for ASCVD
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2024 - 2027A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Zilebesiran Used as Add-on Therapy in Adult Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
Clinical TrialPrincipal Investigator · Awarded by Alnylam Pharmaceuticals · 2024 - 2026SEER-CV Registry (EFFECTIVENESS OF PCSK9I IN THE PREVENTION OF CARDIOVASCULAR DISEASE: A GLOBAL REGISTRY REAL WORLD DATA IN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2021 - 2026Lorundrostat in Uncontrolled HTN
Clinical TrialPrincipal Investigator · Awarded by Mineralys Therapeutics, LLC · 2023 - 2025Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care
ResearchCo Investigator · Awarded by National Cancer Institute · 2020 - 2025REVEAL
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2022 - 2024Creating the Learning Healthcare Platform of the Future: High Risk ASCVD Registry for Longitudinal follow up
ResearchPrincipal Investigator · Awarded by Janssen Scientific Affairs, LLC. · 2018 - 2024A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of ASCVD
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2022 - 2023External Relationships
- Amarin
- American Heart Journal
- Amgen, Inc.
- Novartis pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.